CLOs on the Move

LA Hacks

www.lahacks.com

 
LA Hacks is a hackathon hosted at UCLA that brings together over 1,000 students from universities across the nation to challenge themselves and build creative solutions to problems they see in the world.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Technology Lab

We go above and beyond to be your IT safe space. Your goals are our goals, and we want you to have the time to reach them without worrying about IT challenges.

Taboola

Taboola is the leading discovery platform, serving 360B recommendations to over 1B unique visitors every month on some of the Web`s most innovative publisher sites, including USA TODAY, Business Insider, Chicago Tribune, and The Weather Channel. Headquartered in New York City with R&D in Israel, Taboola also has offices in Pasadena, London, and Bangkok. Publishers, marketers, and agencies leverage Taboola to retain users on their sites, monetize their traffic, and distribute their content to drive high-quality audiences.

You Need Me

You Need Me is a Boulder, CO-based company in the Software and Internet sector.

SmartGate Network Solutions

SmartGate Network Solutions is a Berkeley, IL-based company in the Software and Internet sector.

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.